Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.

Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.

Prostate-specific antigen in prostatic carcinoma.

Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.

Prostate specific antigen after irradiation for prostatic carcinoma.

Screening for prostatic carcinoma with prostate specific antigen.

Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics.

Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.

Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients.

Seasonal variation of prostatic acid phosphate and prostate-specific antigen in patients without prostatic malignancy.

Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.

Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma.

Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.

Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia.

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.

Lack of association between prostate-specific acid phosphatase RFLP genotypes and prostatic cancer or benign prostatic hyperplasia.

Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?

Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer.

Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.

Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.

Prostate-specific antigen and diagnosing early malignancies of the prostate.

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.

Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line.

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men.

Suggest Documents

Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.

Prostate-specific antigen in prostatic carcinoma.

Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.

Prostate specific antigen after irradiation for prostatic carcinoma.

Screening for prostatic carcinoma with prostate specific antigen.

Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics.

Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.

Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients.

Seasonal variation of prostatic acid phosphate and prostate-specific antigen in patients without prostatic malignancy.

Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.

Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma.

Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.

Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia.

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.

Lack of association between prostate-specific acid phosphatase RFLP genotypes and prostatic cancer or benign prostatic hyperplasia.

Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?

Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer.

Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.

Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.

Prostate-specific antigen and diagnosing early malignancies of the prostate.

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.

Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line.

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men.

Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.

Recommend Documents

Follow Us